In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Tanabe Pursues Next Generation Vaccines With Medicago, Tag-teams DPP-4 Market With Daiichi Sankyo

This article was originally published in PharmAsia News

Executive Summary

Mitsubishi Tanabe hopes to take on GSK’s Rotarix, the only rotavirus vaccine approved in Japan. And in a crowded DPP-4 field, Mitsubishi looks to double its sales efforts following a deal with Daiichi Sankyo.

You may also be interested in...



Korean Pharmas Rush Into Vaccines: SK Chemicals Breaks Ground For Cell-culture Vaccines With Aid From Xcellerex

SEOUL - South Korea's SK Chemicals joined the race with domestic manufacturers for cell-culture vaccine production, breaking ground June 15 for a cell-culture vaccine plant that will produce vaccines via a biomanufacturing platform from U.S.-based vaccine maker Xcellerex starting in the second half of 2014

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.

Topics

Related Companies

UsernamePublicRestriction

Register

SC080738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel